Open Access

Prophylactic and therapeutic effect of AZT/3TC in RT-SHIV infected Chinese-origin rhesus macaques

AIDS Research and Therapy201411:12

DOI: 10.1186/1742-6405-11-12

Received: 16 November 2013

Accepted: 26 February 2014

Published: 4 March 2014

Abstract

Background

The precise efficacy of nucleoside analogue reverse-transcriptase inhibitors (NRTIs) in preventing and inhibiting virus replication remains unknown in RT-SHIV infected Chinese-origin rhesus macaques (Ch RM).

Findings

Ch RM were inoculated intravenously with 200 TCID50 RT-SHIV and treated by gavage with NRTIs (20 mg AZT and 10 mg 3TC twice per day) for four consecutive weeks beginning at one hour, on day 217 or 297 post inoculation, respectively. Treatment with AZT/3TC inhibited transiently RT-SHIV replication during chronic infection, but did not significantly affect peripheral blood CD4+ T cells in macaques. Treatment with AZT/3TC at 1 hour post infection prevented RT-SHIV infection in two out of four animals during the 120-day observation period.

Conclusions

Therefore, the Ch RM model with RT-SHIV infection can be used to evaluate the efficacy of new NRTIs.

Keywords

RT-SHIV Animal model Chinese-origin rhesus macaque Post-exposure prophylaxis Therapy

Findings

Animal models, such as non-human primate (NHP) models, are very useful for the preclinical evaluation of anti-viral drugs and microbicides[13]. Due to a low sensitivity of simian immunodeficiency virus (SIV) to non-nucleoside reverse transcriptase inhibitors (NNRTIs) and some nucleoside reverse transcriptase inhibitors (NRTIs), especially for post-exposure prophylaxis (PEP), a number of RT-SHIV strains have been constructed to evaluate the activity of HIV-specific drugs and microbicides both in vitro and in macaques[48]. RT-SHIV carry HIV-1 reverse transcriptase (RT) gene, which is the target of NNRTIs and NRTIs, suitable for evaluating the efficacy of HIV RT inhibitors in macaques[1, 9]. Up to now, RT-SHIV is commonly used to study the effect of highly active antiretroviral therapy (HAART) and antiviral resistance in India origin rhesus macaques (In RM)[1], pigtailed monkey[9, 10], and Chinese-origin rhesus macaques (Ch RM)[11]. An increasing body of evidence demonstrates that Ch RM are useful in evaluating the pathogenesis, vaccine, and therapeutic strategies for HIV/AIDS infection[11]; however, Ch RM are different from In RM in viral infection, immunological response, and host genetic background[12, 13]. It is important to evaluate the virus and infectious character in Ch RM. For example, Pal et al. characterized vaginal transmission of RT-SHIV in Ch RM and showed that RT-SHIV isolates were sensitive to RT inhibitors in vitro[11]. However, the precise efficacy of RT inhibitors in preventing and inhibiting virus replication remains unknown in RT-SHIV/TC infected Ch RM model. In this study, we choose two representative NRTIs, zidovudine (AZT) and lamivudine (3TC), to study their effect on preventing and inhibiting virus replication in Ch RM.

Twelve healthy Ch RMs at 3 years of age (weighing at 4 kg, equal number of males and females) were born and housed in a specific pathogen free (SPF) facility at Institute of Laboratory Animal Science (ILAS), Chinese Academy of Medical Sciences. All naïve animals were negative for tests of simian type D retroviruses (SRV), simian T cell leukemia virus-1 (STLV), simian immunodeficiency virus (SIV), monkey B virus (BV), and tubercle bacillus (TB). Animal care was compliant with the Institute of Laboratory Animal Science Guidelines for the Care and Use of Laboratory Animals (est. 2006), and the experimental protocol was approved by the Animal Research and Care Committee of ILAS (Additional file1: Supplementary Materials and Methods). Ch RM were inoculated intravenously with 200 TCID50 (3.35 × 105 copies/mL) cell-free RT-SHIV, in which the RT gene of SIVmac239 was replaced with that of HIV-1 clone HXBc2[5, 14, 15] (Additional file1: Supplementary Materials and Methods). This dose was similar to the amount of virus in a contaminated needle (estimated 25 μl of blood from a patient with high viral load) through which individuals obtained a primary infection, and was lower than other studies in In RM[1]. Those macaques were randomized and provided with sterile water during the observation period as the controls[16], or treated by oral gavage twice per day with both 20 mg AZT (Sigma, St. Louis, USA) and 10 mg 3TC (Sigma, calculated, according to body surface area, similar to that of human use)[17] beginning at one hour after virus inoculation for four consecutive weeks as the PEP group. These drug powders were weighed and mixed prior to delivery. Four additional macaques were treated by oral gavage with the same dose of AZT and 3TC twice per day beginning on day 217 or 297 post virus inoculation, when the viremia had reached a plateau, as the therapeutic group. Following inoculation and treatment, the contents of plasma virus and the numbers of peripheral CD4+ T cells were determined longitudinally by quantitative RT-PCR (Additional file1: Supplementary Materials and Methods) and flow cytometry analysis[18] (Additional file1: Supplementary Materials and Methods), respectively.

As expected, plasma RT-SHIV-specific RNA was detected in the control group of macaques and reached a peak of 0.69 ~ 6.30 × 106 copies per ml at 1 or 3 weeks post inoculation (Figure 1), consistent with a previous report that RT-SHIV effectively infects Ch RM[11]. Eight to 12 weeks after infection, RT-SHIV viremia reached a plateau and maintained a high level of 1.0 to 3.5 × 104 copies per ml in the control group of macaques throughout the observation period. Furthermore, treatment with a combination of AZT with 3TC starting on day 297 or 217 post-infection significantly reduced the levels of plasma viral loads in these macaques (G1102V, G1104V, G1112V and G1114V), and the levels of viremia in those experimental monkeys were lower than that of the detection threshold (virus RNA load <100 copies/mL) at most time points post drug treatment (Figure 2). These data indicated that treatment with both AZT and 3TC inhibited RT-SHIV replication in macaques. More importantly, treatment with both AZT and 3TC one hour after inoculation dramatically prevented and inhibited RT-SHIV replication in macaques. Evidentially, there was no detectable viremia and viral RNA in three macaques throughout the drug treatment period, and only moderate levels of viremia were detected in another macaque (G1105V) at the phase of drug treatment. One (G1116V) out of three treated monkeys had viral rebound after the end of drug treatment. Similar patterns of provirus DNA were detected in the PBMC of the different groups of monkeys (data not shown). Interestingly, the numbers of peripheral blood CD4+ T cells at the end of the observation period were similar to that at the baseline, except for one macaque (G1102V) that received AZT/3TC on day 297 post inoculation with nearly 65% reduced numbers of peripheral blood CD4+ T cells (Figures 2 and3). Furthermore, there were no obvious clinical symptoms in the infected animals, including G1102V, and these animals remained healthy during the experimental period. Therefore, treatment with a combination of AZT and 3TC prevented and inhibited RT-SHIV replication, but had little effect on the numbers of peripheral blood CD4+ T cells in macaques.
https://static-content.springer.com/image/art%3A10.1186%2F1742-6405-11-12/MediaObjects/12981_2013_Article_330_Fig1_HTML.jpg
Figure 1

The levels of plasma viral loads and peripheral blood CD4 + T cells in individual control macaques. Data are expressed as the mean number of copies of viral RNA (red line) and peripheral blood CD4+ T cells (blue line) of individual macaques through the observation period. The areas of pockmarks show the time periods with AZT/3TC or water gavage.

https://static-content.springer.com/image/art%3A10.1186%2F1742-6405-11-12/MediaObjects/12981_2013_Article_330_Fig2_HTML.jpg
Figure 2

The levels of plasma viral loads and peripheral blood CD4 + T cells in individual macaques treated with AZT/3TC on day 297 or 217 post inoculation. Data are expressed as the mean number of copies of viral RNA (red line) and peripheral blood CD4+ T cells (blue line) of individual macaques through the observation period. The areas of pockmarks show the time periods with AZT/3TC or water gavage.

https://static-content.springer.com/image/art%3A10.1186%2F1742-6405-11-12/MediaObjects/12981_2013_Article_330_Fig3_HTML.jpg
Figure 3

The levels of plasma viral loads and peripheral blood CD4 + T cells in individual macaques treated with AZT/3TC one hour post inoculation. Data are expressed as the mean number of copies of viral RNA (red line) and peripheral blood CD4+ T cells (blue line) of individual macaques through the observation period. The areas of pockmarks show the time periods with AZT/3TC or water gavage.

This study provided evidence to demonstrate that treatment with AZT/3TC prevented and inhibited RT-SHIV replication in a Ch RM model of AIDS. A number of RT-SHIV strains, in which the RT was replaced with the RT from an HIV-1 clone, have been constructed to evaluate the efficacy and safety of HIV-specific NNRTIs and NRTIs both in vitro and in macaques[1, 5, 6, 19]. These stains of viruses are not only highly sensitive to HIV-1 RT-specific NNRTIs, but also to a variety of NRTIs and protease inhibitors, which inhibit virus replication[1, 15]. Hence, RT-SHIV is an appropriate virus for challenge to evaluate the efficacy of anti-HIV NNRTIs and NRTIs. Although In RM macaque is commonly used in biological studies as non-human primate, the limited numbers of In RM macaques available for research have hampered our studies to understand the AIDS pandemic. In addition, studies of non-human primate in a single model of animals may lead to biased results and misleading findings[20]. The Ch RM have a big population available for research and represent a potential resource of animals for expanding the current research efforts. In this study, we infected Ch RM with 200 TCID50 RT-SHIV and observed that treatment with both AZT and 3TC one hour post inoculation prevented RT-SHIV replication in two out of four macaques and treatment with the same drugs at peak infection inhibited virus replication in four macaques. These data indicated that RT-SHIV was sensitive to NRTIs in Ch RM. Conceivably, treatment with these medicines may effectively prevent HIV replication and AIDS development if a natural infection occurs with a dose of HIV. Our data are consistent with a previous report that prophylactic treatment with a single substance post exposure reduces the probability of an infection[21]. Our results suggest that the animal model infected with RT-SHIV can be used to evaluate new NRTIs for the treatment and prevention of AIDS.

In summary, our data indicate that AZT and 3TC treatment post inoculation of RT-SHIV can prevent and inhibit RT-SHIV replication in Ch RM. Therefore, the RT-SHIV/Ch RM model may be valuable to evaluate NRTIs.

Abbreviations

NRTIs: 

Nucleoside analogue reverse-transcriptase inhibitors

Ch RM: 

Chinese-origin rhesus macaque

NHP: 

Non-human primate

SIV: 

Simian immunodeficiency virus

NNRTIs: 

Non-nucleoside reverse transcriptase inhibitors

PEP: 

Post-exposure prophylaxis

RT: 

Reverse transcriptase

HIV: 

Human immunodeficiency virus

HAART: 

Highly active antiretroviral therapy

In RM: 

India origin rhesus macaque

AZT: 

Zidovudine

3TC: 

Lamivudine

SPF: 

Specific pathogen free

ILAS: 

Institute of Laboratory Animal Science

SRV: 

Simian type D retroviruses

STLV: 

Simian T cell leukemia virus-1

BV: 

Monkey B virus

TB: 

Tubercle bacillus.

Declarations

Acknowledgments

The following reagent was obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH: RT-SHIV (Cat #11342) from Dr. Thomas North and Dr. Joseph Sodroski. This work was supported by the National Science and Technology Major Projects of Infectious Disease (2012ZX10004501-001, 2012ZX10001007-008, 2012ZX10001006-003 and 2013ZX10004608-003).

Authors’ Affiliations

(1)
Comparative Medicine Center, Peking Union Medical College (PUMC)
(2)
Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences(CAMS)
(3)
Key Laboratory of Human Diseases Comparative Medicine, Ministry of Health
(4)
Key Laboratory of Human Diseases Animal Models, State Administration of Traditional Chinese Medicine

References

  1. Jiang Y, Tian B, Saifuddin M, Agy MB, Emau P, Cairns JS, Tsai CC: RT-SHIV, an infectious CCR5-tropic chimeric virus suitable for evaluating HIV reverse transcriptase inhibitors in macaque models. AIDS Res Ther. 2009, 6: 23- 10.1186/1742-6405-6-23PubMed CentralView ArticlePubMedGoogle Scholar
  2. Walker BD, Ahmed R, Plotkin S: Moving ahead an HIV vaccine: use both arms to beat HIV. Nat Med. 2011, 17: 1194-1195. 10.1038/nm.2529View ArticlePubMedGoogle Scholar
  3. Hatziioannou T, Evans DT: Animal models for HIV/AIDS research. Nat Rev Microbiol. 2012, 10: 852-867. 10.1038/nrmicro2911PubMed CentralView ArticlePubMedGoogle Scholar
  4. Balzarini J, Weeger M, Camarasa MJ, De Clercq E, Uberla K: Sensitivity/resistance profile of a simian immunodeficiency virus containing the reverse transcriptase gene of human immunodeficiency virus type 1 (HIV-1) toward the HIV-1-specific non-nucleoside reverse transcriptase inhibitors. Biochem Biophys Res Commun. 1995, 211: 850-856. 10.1006/bbrc.1995.1890View ArticlePubMedGoogle Scholar
  5. Soderberg K, Denekamp L, Nikiforow S, Sautter K, Desrosiers RC, Alexander L: A nucleotide substitution in the tRNA(Lys) primer binding site dramatically increases replication of recombinant simian immunodeficiency virus containing a human immunodeficiency virus type 1 reverse transcriptase. J Virol. 2002, 76: 5803-5806. 10.1128/JVI.76.11.5803-5806.2002PubMed CentralView ArticlePubMedGoogle Scholar
  6. Ambrose Z, Boltz V, Palmer S, Coffin JM, Hughes SH, Kewalramani VN: In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques. J Virol. 2004, 78: 13553-13561. 10.1128/JVI.78.24.13553-13561.2004PubMed CentralView ArticlePubMedGoogle Scholar
  7. Portsmouth SD, Scott CJ: The renaissance of fixed dose combinations: combivir. Ther Clin Risk Manag. 2007, 3: 579-583.PubMed CentralPubMedGoogle Scholar
  8. Panlilio AL, Cardo DM, Grohskopf LA, Heneine W, Ross CS: Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep. 2005, 54: 1-17.PubMedGoogle Scholar
  9. Shao W, Kearney M, Maldarelli F, Mellors JW, Stephens RM, Lifson JD, KewalRamani VN, Ambrose Z, Coffin JM, Palmer SE: RT-SHIV subpopulation dynamics in infected macaques during anti-HIV therapy. Retrovirology. 2009, 6: 101- 10.1186/1742-4690-6-101PubMed CentralView ArticlePubMedGoogle Scholar
  10. Cole AM, Patton DL, Rohan LC, Cole AL, Cosgrove-Sweeney Y, Rogers NA, Ratner D, Sassi AB, Lackman-Smith C, Tarwater P, Ramratnam B, Ruchala P, Lehrer RI, Waring AJ, Gupta P: The formulated microbicide RC-101 was safe and antivirally active following intravaginal application in pigtailed macaques. PLoS One. 2010, 5: e15111- 10.1371/journal.pone.0015111PubMed CentralView ArticlePubMedGoogle Scholar
  11. Pal R, Nuttall J, Galmin L, Weiss D, Chung HK, Romano J: Characterization of vaginal transmission of a simian human immunodeficiency virus (SHIV) encoding the reverse transcriptase gene from HIV-1 in Chinese rhesus macaques. Virology. 2009, 386: 102-108. 10.1016/j.virol.2009.01.002View ArticlePubMedGoogle Scholar
  12. Joag SV, Stephens EB, Adams RJ, Foresman L, Narayan O: Pathogenesis of SIVmac infection in Chinese and Indian rhesus macaques: effects of splenectomy on virus burden. Virology. 1994, 200: 436-446. 10.1006/viro.1994.1207View ArticlePubMedGoogle Scholar
  13. Marthas ML, Lu D, Penedo MC, Hendrickx AG, Miller CJ: Titration of an SIVmac251 stock by vaginal inoculation of Indian and Chinese origin rhesus macaques: transmission efficiency, viral loads, and antibody responses. AIDS Res Hum Retroviruses. 2001, 17: 1455-1466. 10.1089/088922201753197123PubMed CentralView ArticlePubMedGoogle Scholar
  14. Uberla K, Stahl-Hennig C, Bottiger D, Matz-Rensing K, Kaup FJ, Li J, Haseltine WA, Fleckenstein B, Hunsmann G, Oberg B: Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors. Proc Natl Acad Sci U S A. 1995, 92: 8210-8214. 10.1073/pnas.92.18.8210PubMed CentralView ArticlePubMedGoogle Scholar
  15. North TW, Van Rompay KK, Higgins J, Matthews TB, Wadford DA, Pedersen NC, Schinazi RF: Suppression of virus load by highly active antiretroviral therapy in rhesus macaques infected with a recombinant simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1. J Virol. 2005, 79: 7349-7354. 10.1128/JVI.79.12.7349-7354.2005PubMed CentralView ArticlePubMedGoogle Scholar
  16. Le Grand R, Vaslin B, Larghero J, Neidez O, Thiebot H, Sellier P, Clayette P, Dereuddre-Bosquet N, Dormont D: Post-exposure prophylaxis with highly active antiretroviral therapy could not protect macaques from infection with SIV/HIV chimera. AIDS. 2000, 14: 1864-1866. 10.1097/00002030-200008180-00029View ArticlePubMedGoogle Scholar
  17. Yoshimura K, Ido E, Akiyama H, Kimura T, Aoki M, Suzuki H, Mitsuya H, Hayami M, Matsushita S: The impact of highly active antiretroviral therapy by the oral route on the CD8 subset in monkeys infected chronically with SHIV 89.6P. J Virol Methods. 2003, 112: 121-128. 10.1016/S0166-0934(03)00201-5View ArticlePubMedGoogle Scholar
  18. Xue J, Cong Z, Xiong J, Wang W, Jiang H, Chen T, Wu F, Liu K, Su A, Ju B, Chen Z, Couto MA, Wei Q, Qin C: Repressive effect of primary virus replication on superinfection correlated with gut-derived central memory CD4(+) T cells in SHIV-infected Chinese rhesus macaques. PLoS One. 2013, 8: e72295- 10.1371/journal.pone.0072295PubMed CentralView ArticlePubMedGoogle Scholar
  19. Ambrose Z, Palmer S, Boltz VF, Kearney M, Larsen K, Polacino P, Flanary L, Oswald K, Piatak M, Smedley J, Shao W, Bischofberger N, Maldarelli F, Kimata JT, Mellors JW, Hu SL, Coffin JM, Lifson JD, KewalRamani VN: Suppression of viremia and evolution of human immunodeficiency virus type 1 drug resistance in a macaque model for antiretroviral therapy. J Virol. 2007, 81: 12145-12155. 10.1128/JVI.01301-07PubMed CentralView ArticlePubMedGoogle Scholar
  20. Burdo TH, Marcondes MC, Lanigan CM, Penedo MC, Fox HS: Susceptibility of Chinese rhesus monkeys to SIV infection. AIDS. 2005, 19: 1704-1706. 10.1097/01.aids.0000186823.76230.33View ArticlePubMedGoogle Scholar
  21. Landovitz RJ, Currier JS: Clinical practice. Postexposure prophylaxis for HIV infection. N Engl J Med. 2009, 361: 1768-1775. 10.1056/NEJMcp0904189View ArticlePubMedGoogle Scholar

Copyright

© Wang et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement